| 摘要: |
| 目的:对艾加莫德(efgartigimod)和依库珠单抗(eculizumab)进行临床综合评价,为医院新药引进和临床合理用药提供参
考。方法:依据《中国医疗机构药品评价与遴选快速指南(第二版)》,从药学特性、有效性、安全性、经济性及其他属性5 个方面
对两种药物进行综合评分。结果:艾加莫德总分50. 56 分,依库珠单抗总分53. 70 分。两药虽非重症肌无力治疗首选,但均被
国内外指南推荐为疗效确切的备选方案。艾加莫德因上市较晚,目前缺乏<18 岁人群研究数据,需进一步评估其在该人群中应
用的安全性、有效性及剂量反应。结论:艾加莫德和依库珠单抗评分均<60. 00 分,为同等条件下,暂不优先考虑。本次综合评
价为医院合理应用两药提供了决策支持,临床应结合患儿个体情况慎重选择。 |
| 关键词: 艾加莫德 依库珠单抗 重症肌无力 综合评价 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2025.11.013 |
|
| 基金项目:基金项目:2024 年中国药学会科普研究重点项目课题,编号CMEI2024KPYJ00105 |
|
| Clinical Comprehensive Evaluation of Efgartigimod and Eculizumab Based on A Quick Guideline for DrugEvaluation and Selection in Chinese Medical Institutions (the Second Edition) |
| Jiang Junfei1, Gao Yue1, Tian Xingmin2, Qin Yang2 |
| (1. Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of
Medicine, Shanghai 201600, China; 2. Zhaoyang District Hospital of Traditional Chinese Medicine, Yunnan Zhaotong 657000,
China) |
| Abstract: |
| Objective: To perform comprehensive clinical evaluation of efgartigimod and eculizumab, and to provide reference for the
introduction of new drugs in hospitals and rational use of drugs in clinical practice. Methods: Following A Quick Guideline for Drug
Evaluation and Selection in Chinese Medical Institutions (the Second Edition), both drugs were assessed comprehensively across five
dimensions: pharmaceutical characteristics, efficacy, safety, economic considerations, and additional attributes. Results: Efgartigimod
received a score of 50. 56 points while eculizumab scored 53. 70 points. Neither drug was considered as the first-line treatment for myasthenia gravis, yet both drugs were recommended as effective alternatives by domestic and foreign guidelines. Due to the late
marketing of efgartigimod, there was a lack of research data for individuals under the age of 18 years, further assessment was needed to
evaluate its safety, efficacy and dose-response. Conclusion: The scores for both drugs are <60. 00 pints, under the same conditions,
efgartigimod and eculizumab are not given priority for consideration. This comprehensive evaluation provides decision support for the
rational use of two drugs in the hospital, clinicians should carefully select drugs based on the individual conditions. |
| Key words: efgartigimod eculizumab myasthenia gravis comprehensive evaluation |
